2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a

From Wikipedia, the free encyclopedia
(Redirected from Photochlor)
Jump to navigation Jump to search
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
File:Photochlor.png
Names
Other names
Photochlor
Identifiers
3D model (JSmol)
Abbreviations HPPH
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value).Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
E number Lua error in Module:Wikidata at line 880: attempt to index field 'wikibase' (a nil value).
UNII
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
  • InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,40-41H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1 checkY
    Key: ODJVLHDVEGAIAW-NMWXTPPCSA-N checkY
  • InChI=1/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,40-41H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1
    Key: ODJVLHDVEGAIAW-NMWXTPPCBI
  • CCCCCCOC(C)C1=C2C=C3C(=C(C(=CC4=NC5=C(CC(=O)C5=C4C)C6=NC(=CC(=C1C)N2)[C@H]([C@@H]6CCC(=O)O)C)N3)CC)C
Properties
C39H48N4O4
Molar mass 636.837 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) is a photosensitiser chemical that is used in photodynamic therapy.[1]

It is being developed under the brand name Photochlor.

Clinical trials

[edit | edit source]

A phase I/II clinical trial started in 1997 for esophageal cancer.[2]

A phase II trial for non-small cell lung cancer is due to run from 2007 to 2011.[3]

References

[edit | edit source]
[edit | edit source]